{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T21:06:45Z","timestamp":1765487205498,"version":"3.40.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Die Frage nach der Kosteneffektivit\u00e4t medizinischer Interventionen ist eine der zentralen Fragen der Gesundheits\u00f6konomie. Dieses narrative Review untersucht die Kosteneffektivit\u00e4t von Impfungen gegen Influenza, SARS-CoV\u20112 und das respiratorische Synzytial-Virus (RSV) unter Ber\u00fccksichtigung aktueller gesundheits\u00f6konomischer Analysen. Die j\u00e4hrliche Influenza-Impfung und die Auffrischungsimpfung gegen SARS-CoV\u20112 in den Jahren 2023 und 2024 erweisen sich, insbesondere in Hochrisikogruppen, als kosteneffektiv und teilweise sogar kostensparend. F\u00fcr die RSV-Impfung, die 2023 zugelassen wurde, ist die Kosteneffektivit\u00e4t weniger klar. Sie h\u00e4ngt stark von der Altersgruppe und der Bereitschaft ab, f\u00fcr ein gewonnenes qualit\u00e4tsadjustiertes Lebensjahr (QALY) zu zahlen. Die Analyse zeigt, dass die Bewertung von Impfungen eine erhebliche Datenmenge erfordert. Modellrechnungen zu Impfungen m\u00fcssen neben direkten Schutzwirkungen auch indirekte Effekte, wie die Reduzierung von \u00dcbertragungen in der Bev\u00f6lkerung bei h\u00f6heren Impfraten, ber\u00fccksichtigen. Sensitivit\u00e4tsanalysen verdeutlichen, dass Faktoren wie Impfstoffkosten, Effektivit\u00e4t und Krankheitsinzidenz entscheidenden Einfluss auf die Kosteneffektivit\u00e4t haben k\u00f6nnen. Eine der gr\u00f6\u00dften Herausforderungen in gesundheits\u00f6konomischen Analysen ist die Fragmentierung von Gesundheitsdaten in vielen L\u00e4ndern, was umfassende und pr\u00e4zise Bewertungen erschwert. Initiativen wie der europ\u00e4ische Gesundheitsdatenraum k\u00f6nnten hier Abhilfe schaffen und eine evidenzbasierte Entscheidungsfindung in der Gesundheitspolitik unterst\u00fctzen. Insgesamt bleibt die Kosteneffektivit\u00e4t von Impfungen abh\u00e4ngig von zahlreichen Faktoren, wobei insbesondere die SARS-CoV-2- und Influenza-Impfungen in den betrachteten Szenarien eine positive Bewertung erhalten.<\/jats:p>","DOI":"10.1007\/s00103-025-04022-8","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T12:39:45Z","timestamp":1741091985000},"page":"451-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kosteneffizienz von Impfungen: \u00dcber die Komplexit\u00e4t gesundheits\u00f6konomischer Analysen zur Influenza\u2011, SARS-CoV-2- und RSV-Impfung","Cost effectiveness of vaccinations: on the complexity of health economic analyses of influenza, SARS-CoV-2 and RSV vaccination"],"prefix":"10.1007","volume":"68","author":[{"given":"Peter","family":"Klimek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"4022_CR1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1136\/bmj.307.6907.793","volume":"307","author":"R Robinson","year":"1993","unstructured":"Robinson\u00a0R (1993) Cost-effectiveness analysis. BMJ 307:793. https:\/\/doi.org\/10.1136\/bmj.307.6907.793","journal-title":"BMJ"},{"key":"4022_CR2","volume-title":"Cost-effectiveness analysis: Methods and applications","author":"HM Levin","year":"2001","unstructured":"Levin\u00a0HM, McEwan\u00a0PJ (2001) Cost-effectiveness analysis: Methods and applications, 2.\u00a0Aufl. SAGE, Thousand Oaks","edition":"2"},{"key":"4022_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0272989x8900900209","volume":"9","author":"A Mehrez","year":"1989","unstructured":"Mehrez\u00a0A, Gafni\u00a0A (1989) Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making 9:142\u2013149. https:\/\/doi.org\/10.1177\/0272989x8900900209","journal-title":"Med Decis Making"},{"issue":"9","key":"4022_CR4","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.socscimed.2005.10.023","volume":"62","author":"A Gafni","year":"2006","unstructured":"Gafni\u00a0A, Birch\u00a0S (2006) Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 62(9):2091\u20132100. https:\/\/doi.org\/10.1016\/j.socscimed.2005.10.023","journal-title":"Soc Sci Med"},{"key":"4022_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","volume":"26","author":"C McCabe","year":"2008","unstructured":"McCabe\u00a0C, Claxton\u00a0K, Culver\u00a0A (2008) The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 26:733\u2013744. https:\/\/doi.org\/10.2165\/00019053-200826090-00004","journal-title":"PharmacoEconomics"},{"key":"4022_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala\u00a0P, Ochalek\u00a0J, Leech\u00a0AA et\u00a0al (2018) Cost-Effectiveness Thresholds: the Past, the Present and the Future. PharmacoEconomics 36:509\u2013522. https:\/\/doi.org\/10.1007\/s40273-017-0606-1","journal-title":"PharmacoEconomics"},{"key":"4022_CR7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1478-7547-1-8","volume":"1","author":"R Hutubessy","year":"2003","unstructured":"Hutubessy\u00a0R, Chisholm\u00a0D, Edejer\u00a0TT (2003) Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc 1:8. https:\/\/doi.org\/10.1186\/1478-7547-1-8","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"4022_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2021.08.014","volume":"25","author":"J Kazibwe","year":"2022","unstructured":"Kazibwe\u00a0J, Gheorghe\u00a0A, Wilson\u00a0D et\u00a0al (2022) The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A\u00a0Review. Value Health 25(3):385\u2013389. https:\/\/doi.org\/10.1016\/j.jval.2021.08.014","journal-title":"Value Health"},{"issue":"12","key":"4022_CR9","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/blt.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram\u00a0MY, Lauer\u00a0JA, De Joncheere\u00a0K et\u00a0al (2016) Cost-effectiveness thresholds: pros and cons. Bull World Health Organ 94(12):925\u2013930. https:\/\/doi.org\/10.2471\/blt.15.164418","journal-title":"Bull World Health Organ"},{"issue":"6","key":"4022_CR10","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/s2214-109x(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere\u00a0A, Drummond\u00a0M, Palacios\u00a0A et\u00a0al (2023) Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health 11(6):e833\u2013e842. https:\/\/doi.org\/10.1016\/s2214-109x(23)00162-6","journal-title":"Lancet Glob Health"},{"key":"4022_CR11","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s10198-021-01338-5","volume":"22","author":"N M\u00fchlberger","year":"2021","unstructured":"M\u00fchlberger\u00a0N, Sroczynski\u00a0G, Gogollari\u00a0A et\u00a0al (2021) Cost effectiveness of breast cancer screening and prevention: a\u00a0systematic review with a\u00a0focus on risk-adapted strategies. Eur J Health Econ 22:1311\u20131344. https:\/\/doi.org\/10.1007\/s10198-021-01338-5","journal-title":"Eur J Health Econ"},{"issue":"5","key":"4022_CR12","doi-asserted-by":"publisher","first-page":"e2310650","DOI":"10.1001\/jamanetworkopen.2023.10650","volume":"6","author":"F Menegale","year":"2023","unstructured":"Menegale\u00a0F, Manica\u00a0M, Zardini\u00a0A et\u00a0al (2023) Evaluation of Waning of SARS-CoV\u20112 Vaccine-Induced Immunity: A\u00a0Systematic Review and Meta-analysis. JAMA Netw Open 6(5):e2310650. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.10650","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4022_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2020.11.002","volume":"24","author":"F Zeevat","year":"2021","unstructured":"Zeevat\u00a0F, Cr\u00e9pey\u00a0P, Dolk\u00a0F et\u00a0al (2021) Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination. Value Health 24(1):3\u201310. https:\/\/doi.org\/10.1016\/j.jval.2020.11.002","journal-title":"Value Health"},{"issue":"3","key":"4022_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/21645515.2016.1242541","volume":"13","author":"A Brogan","year":"2017","unstructured":"Brogan\u00a0A, Talbird\u00a0S, Davis\u00a0A et\u00a0al (2017) Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A\u00a0dynamic transmission modeling approach. Hum Vaccin Immunother 13(3):533\u2013543. https:\/\/doi.org\/10.1080\/21645515.2016.1242541","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"4022_CR15","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1186\/s12889-020-09409-7","volume":"20","author":"P Cr\u00e9pey","year":"2020","unstructured":"Cr\u00e9pey\u00a0P, Boiron\u00a0L, Araujo\u00a0R et\u00a0al (2020) Impact of quadrivalent influenza vaccines in Brazil: a\u00a0cost-effectiveness analysis using an influenza transmission model. BMC Public Health 20(1):1374. https:\/\/doi.org\/10.1186\/s12889-020-09409-7","journal-title":"BMC Public Health"},{"key":"4022_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12879-015-1193-4","volume":"15","author":"E Thommes","year":"2015","unstructured":"Thommes\u00a0E, Ismaila\u00a0A, Chit\u00a0A et\u00a0al (2015) Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a\u00a0dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis 15:465. https:\/\/doi.org\/10.1186\/s12879-015-1193-4","journal-title":"BMC Infect Dis"},{"issue":"1","key":"4022_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jval.2020.10.011","volume":"24","author":"P de Boer","year":"2020","unstructured":"de Boer\u00a0P, Nagy\u00a0L, Dolk\u00a0F et\u00a0al (2020) Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands. Value Health 24(1):19\u201331. https:\/\/doi.org\/10.1016\/j.jval.2020.10.011","journal-title":"Value Health"},{"issue":"6","key":"4022_CR18","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3390\/vaccines10060932","volume":"10","author":"G Shin","year":"2022","unstructured":"Shin\u00a0G, Kang\u00a0D, Cheong\u00a0H et\u00a0al (2022) Cost-Effectiveness of Extending the National Influenza Vaccination Program in South Korea: Does Vaccination of Older Adults Provide Health Benefits to the Entire Population? Vaccines 10(6):932. https:\/\/doi.org\/10.3390\/vaccines10060932","journal-title":"Vaccines"},{"issue":"6","key":"4022_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/vaccines9060598","volume":"9","author":"M Kohli","year":"2021","unstructured":"Kohli\u00a0M, Maschio\u00a0M, Mould-Quevedo\u00a0J et\u00a0al (2021) The Cost-Effectiveness of Expanding Vaccination with a\u00a0Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom. Vaccines 9(6):598. https:\/\/doi.org\/10.3390\/vaccines9060598","journal-title":"Vaccines"},{"issue":"11","key":"4022_CR20","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1080\/21645515.2021.1971017","volume":"17","author":"M Kohli","year":"2021","unstructured":"Kohli\u00a0M, Maschio\u00a0M, Mould-Quevedo\u00a0J et\u00a0al (2021) The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom. Hum Vaccin Immunother 17(11):4603\u20134610. https:\/\/doi.org\/10.1080\/21645515.2021.1971017","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"4022_CR21","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/vaccines10091386","volume":"10","author":"M Kohli","year":"2022","unstructured":"Kohli\u00a0M, Maschio\u00a0M, Cartier\u00a0S et\u00a0al (2022) The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany. Vaccines 10(9):1386. https:\/\/doi.org\/10.3390\/vaccines10091386","journal-title":"Vaccines"},{"issue":"10","key":"4022_CR22","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/vaccines9101095","volume":"9","author":"V Nguyen","year":"2021","unstructured":"Nguyen\u00a0V, Hilsky\u00a0Y, Mould-Quevedo\u00a0J (2021) The Epidemiological and Economic Impact of a\u00a0Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A\u00a0Dynamic Modeling Approach. Vaccines 9(10):1095. https:\/\/doi.org\/10.3390\/vaccines9101095","journal-title":"Vaccines"},{"issue":"9","key":"4022_CR23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/aje\/kww229","volume":"185","author":"J DePasse","year":"2017","unstructured":"DePasse\u00a0J, Smith\u00a0K, Raviotta\u00a0J et\u00a0al (2017) Does Choice of Influenza Vaccine Type Change Disease Burden and Cost-Effectiveness in the United States? An Agent-Based Modeling Study. Am J Epidemiol 185(9):822\u2013831. https:\/\/doi.org\/10.1093\/aje\/kww229","journal-title":"Am J Epidemiol"},{"issue":"32","key":"4022_CR24","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.1016\/j.vaccine.2017.05.093","volume":"35","author":"J DePasse","year":"2017","unstructured":"DePasse\u00a0J, Nowalk\u00a0M, Smith\u00a0K et\u00a0al (2017) Does cost-effectiveness of influenza vaccine choice vary across the U.S.? An agent-based modeling study. Vaccine 35(32):3974\u20133981. https:\/\/doi.org\/10.1016\/j.vaccine.2017.05.093","journal-title":"Vaccine"},{"issue":"12","key":"4022_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.jval.2019.07.001","volume":"22","author":"M Yue","year":"2019","unstructured":"Yue\u00a0M, Dickens\u00a0BL, Yoong\u00a0J et\u00a0al (2019) Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A\u00a0Modeling Study. Value Health 22(12):1345\u20131354. https:\/\/doi.org\/10.1016\/j.jval.2019.07.001","journal-title":"Value Health"},{"issue":"1","key":"4022_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12916-019-1471-x","volume":"18","author":"PT de Boer","year":"2020","unstructured":"de Boer\u00a0PT, Backer\u00a0JA, van Hoek\u00a0AJ, Wallinga\u00a0J (2020) Vaccinating children against influenza: overall cost-effective with potential for undesirable outcomes. BMC Med 18(1):11. https:\/\/doi.org\/10.1186\/s12916-019-1471-x","journal-title":"BMC Med"},{"issue":"1","key":"4022_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/vaccines11010161","volume":"11","author":"Z Pi","year":"2023","unstructured":"Pi\u00a0Z, Aoyagi\u00a0K, Arima\u00a0K et\u00a0al (2023) Optimization of Elderly Influenza and Pneumococcal Immunization Programs in Beijing, China Using Health Economic Evaluations: A\u00a0Modeling Study. Vaccines 11(1):161. https:\/\/doi.org\/10.3390\/vaccines11010161","journal-title":"Vaccines"},{"issue":"4","key":"4022_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/vaccines10040599","volume":"10","author":"M Maschio","year":"2022","unstructured":"Maschio\u00a0M, Kohli\u00a0M, Ashraf\u00a0M et\u00a0al (2022) An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom. Vaccines 10(4):599. https:\/\/doi.org\/10.3390\/vaccines10040599","journal-title":"Vaccines"},{"issue":"29","key":"4022_CR29","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1016\/j.vaccine.2023.04.069","volume":"41","author":"EA DeLuca","year":"2023","unstructured":"DeLuca\u00a0EA, Gebremariam\u00a0A, Rose\u00a0AM et\u00a0al (2023) Cost-effectiveness of routine annual influenza vaccination by age and risk status. Vaccine 41(29):4239\u20134248. https:\/\/doi.org\/10.1016\/j.vaccine.2023.04.069","journal-title":"Vaccine"},{"issue":"5","key":"4022_CR30","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1080\/14737167.2021.1925110","volume":"21","author":"S Boccalini","year":"2021","unstructured":"Boccalini\u00a0S, Bechini\u00a0A, Moscadelli\u00a0A et\u00a0al (2021) Cost-effectiveness of childhood influenza vaccination in Europe: results from a\u00a0systematic review. Expert Rev Pharmacoecon Outcomes Res 21(5):911\u2013922. https:\/\/doi.org\/10.1080\/14737167.2021.1925110","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"4022_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jval.2020.05.022","volume":"24","author":"S Scholz","year":"2021","unstructured":"Scholz\u00a0S, Weidemann\u00a0F, Damm\u00a0O et\u00a0al (2021) Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. Value Health 24(1):32\u201340. https:\/\/doi.org\/10.1016\/j.jval.2020.05.022","journal-title":"Value Health"},{"key":"4022_CR32","doi-asserted-by":"publisher","first-page":"06001","DOI":"10.7189\/jogh.13.06001","volume":"13","author":"AM Utami","year":"2023","unstructured":"Utami\u00a0AM, Rendrayani\u00a0F, Khoiry\u00a0QA et\u00a0al (2023) Economic evaluation of COVID-19 vaccination: A\u00a0systematic review. J\u00a0Glob Health 13:6001. https:\/\/doi.org\/10.7189\/jogh.13.06001","journal-title":"J Glob Health"},{"issue":"2","key":"4022_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/tropicalmed8020091","volume":"8","author":"K Sirison","year":"2023","unstructured":"Sirison\u00a0K, Nittayasoot\u00a0N, Techasuwanna\u00a0R et\u00a0al (2023) Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance. Trop Med Infect Dis 8(2):91. https:\/\/doi.org\/10.3390\/tropicalmed8020091","journal-title":"Trop Med Infect Dis"},{"key":"4022_CR34","doi-asserted-by":"publisher","first-page":"1280412","DOI":"10.3389\/fpubh.2023.1280412","volume":"11","author":"W Choi","year":"2023","unstructured":"Choi\u00a0W, Shim\u00a0E (2023) Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a\u00a0transmission dynamic model. Front Public Health 11:1280412. https:\/\/doi.org\/10.3389\/fpubh.2023.1280412","journal-title":"Front Public Health"},{"issue":"9","key":"4022_CR35","doi-asserted-by":"publisher","first-page":"e0310427","DOI":"10.1371\/journal.pone.0310427","volume":"19","author":"C Mahasing","year":"2024","unstructured":"Mahasing\u00a0C, Suphanchaimat\u00a0R, Teekasap\u00a0P et\u00a0al (2024) Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand. PLoS ONE 19(9):e310427. https:\/\/doi.org\/10.1371\/journal.pone.0310427","journal-title":"PLoS ONE"},{"issue":"1","key":"4022_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/13696998.2023.2290388","volume":"27","author":"K Joshi","year":"2024","unstructured":"Joshi\u00a0K, Scholz\u00a0S, Maschio\u00a0M et\u00a0al (2024) Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany. J\u00a0Med Econ 27(1):39\u201350. https:\/\/doi.org\/10.1080\/13696998.2023.2290388","journal-title":"J Med Econ"},{"issue":"1","key":"4022_CR37","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1080\/13696998.2023.2281083","volume":"26","author":"M Kohli","year":"2023","unstructured":"Kohli\u00a0M, Maschio\u00a0M, Joshi\u00a0K et\u00a0al (2023) The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States. J\u00a0Med Econ 26(1):1532\u20131545. https:\/\/doi.org\/10.1080\/13696998.2023.2281083","journal-title":"J Med Econ"},{"issue":"1","key":"4022_CR38","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/13696998.2024.2413288","volume":"27","author":"M Kohli","year":"2024","unstructured":"Kohli\u00a0M, Maschio\u00a0M, Lee\u00a0A et\u00a0al (2024) The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom. J\u00a0Med Econ 27(1):1359\u20131372. https:\/\/doi.org\/10.1080\/13696998.2024.2413288","journal-title":"J Med Econ"},{"key":"4022_CR39","doi-asserted-by":"publisher","first-page":"126294","DOI":"10.1016\/j.vaccine.2024.126294","volume":"42","author":"D Hutton","year":"2024","unstructured":"Hutton\u00a0D, Prosser\u00a0L, Rose\u00a0A et\u00a0al (2024) Cost-effectiveness of vaccinating adults aged 60\u00a0years and older against respiratory syncytial virus. Vaccine 42:126294. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126294","journal-title":"Vaccine"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-025-04022-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-025-04022-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-025-04022-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T11:10:22Z","timestamp":1743333022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-025-04022-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["4022"],"URL":"https:\/\/doi.org\/10.1007\/s00103-025-04022-8","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"type":"print","value":"1436-9990"},{"type":"electronic","value":"1437-1588"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0Klimek gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}